Evidence map›Paper›PMID 31664971›Full record

ArticleBMC public health2019

Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product.

Smilja Djurdjevic, Laszlo Pecze, Rolf Weitkunat, Frank Luedicke, John Fry, Peter Lee

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Smilja DjurdjevicPhilip Morris R&D, Philip Morris Products SA, Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Laszlo PeczeRoute du Midi 1, CH-1723, Marly, Switzerland.
Rolf WeitkunatPhilip Morris R&D, Philip Morris Products SA, Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Frank LuedickePhilip Morris R&D, Philip Morris Products SA, Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
John FryRoelee Statistics Ltd, 17 Cedar Road, Sutton, Surrey, SM2 5DA, UK.
Peter LeeP N Lee Statistics and Computing Ltd, 17 Cedar Road, Sutton, Surrey, SM2 5DA, UK. PeterLee@pnlee.co.uk.
Philip Morris International (Switzerland) · CHP N Lee Statistics and Computing (United Kingdom) · GB

Funding

Philip Morris Products SA. Project Agreement 28
6 · The paper itself

Abstract

backgroundWe have developed an approach for modelling the health impact of introducing new smoke-free tobacco products. We wished to compare its estimates with those of alternative approaches, when applied to snus, used in Sweden for many years.

methodsModelling was restricted to men aged 30-79 years for 1980-2009 and to four smoking-related diseases. Mortality data were extracted for Sweden and other European countries. Published data provided Swedish prevalence estimates for combinations of never/former/current smoking and snus use, and smoking prevalence estimates for other European countries. Approach 1 compares mortality in Sweden and in other countries with a smoking prevalence similar to Sweden's prevalence of combined smoking/snus use. Approaches 2 and 3 compare mortality in Sweden with hypothetical mortality had snus users smoked. Approach 3 uses our health impact model, individuals starting with the tobacco prevalence of Sweden in 1980. Tobacco histories during 30-year follow-up were then estimated using transition probabilities, with risk derived using a negative exponential model. Approach 2 uses annual tobacco prevalence estimates coupled with estimates of relative risk of current and former smokers regardless of history. The main applications of Approaches 2 and 3 assume that only smoking affects mortality, though sensitivity analyses using Approach 3 allow for risk to vary in snus users and dual users.

resultsUsing Approach 2, estimated mortality increases in Sweden in 1980-2009 had snus not been introduced were: lung cancer 8786; COPD 1781; IHD 10,409; stroke 1720. The main Approach 3 estimates were similar (7931, 1969; 12,501; 1901). They decreased as risk in snus users and dual users increased. Approach 1 estimates differed wildly (77,762, 32,538; 77,438; 76,946), remaining very different following correction for differences between Sweden and the comparison countries in non-smoking-related disease mortality.

conclusionsApproach 1 is unreliable, accounting inadequately for non-tobacco factors affecting mortality. Approaches 2 and 3 provide reasonably similar approximate estimates of the mortality increase had snus not been available, but have differing advantages and disadvantages. Only Approach 3 considers tobacco history, but develops histories using tobacco transition probabilities, which is possibly less reliable than using estimated tobacco prevalences at each follow-up year.

Indexed as

Models, TheoreticalPopulation HealthAdultAgedHumansMaleMiddle AgedMortalityPrevalenceReproducibility of ResultsRiskSmokingSwedenTobacco, SmokelessAttributable riskHarm reductionModellingSmoke-free tobacco productSmokingSnusValidation

Identifiers

PMID31664971
PMCPMC6819486
OpenAlexW2982362811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.